Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of BHT-3021 injections given weekly for
12 weeks and to evaluate the effect of BHT-3021 on antibody and immune (T cell) responses to
autoantigens (e.g. insulin). Changes in pancreatic beta cell function, insulin requirements
and blood glucose levels will also be evaluated.